Evercore ISI Keeps a Hold Rating on Voyager Therapeutics (VYGR)

By Ryan Adsit

Evercore ISI analyst Joshua Schimmer maintained a Hold rating on Voyager Therapeutics (VYGRResearch Report) on November 22 and set a price target of $18.00. The company’s shares closed last Monday at $14.26.

According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 10.2% and a 50.7% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Voyager Therapeutics with a $22.67 average price target, implying a 58.1% upside from current levels. In a report issued on November 7, Morgan Stanley also maintained a Hold rating on the stock with a $24.00 price target.

See today’s analyst top recommended stocks >>

Based on Voyager Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.01 million. In comparison, last year the company had a GAAP net loss of $20.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.